异动解读2025-10-01
美国制药巨头辉瑞（PFE）股价周二盘中大涨5.05%，引发市场广泛关注。据多方消息源透露，辉瑞公司将与特朗普政府达成一项重要的药品定价协议，这被认为是推动股价上涨的主要原因。
根据报道，辉瑞首席执行官Albert Bourla预计将宣布在美国投资700亿美元用于药品生产和研发。这一大规模投资计划显示了辉瑞对美国市场的长期承诺，有望增强其在制药行业的竞争力。与此同时，辉瑞还将通过医疗补助计划以较低价格销售其部分药品，这一举措可能会扩大辉瑞产品的市场覆盖范围，提高其药品的可及性。
此外，白宫计划推出名为"TrumpRx"的药品购买网站，允许美国民众直接通过政府网站以折扣价购买某些药品。虽然目前该网站的具体细节尚不清楚，但这一创新性的药品销售渠道可能为辉瑞带来新的业务机会。分析人士认为，这些利好消息综合推动了辉瑞股价的显著上涨，投资者对公司未来发展前景持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
